Indeed, it was previously described that the ISR response, with concomitant activation of ATF4 and its targets were associated with poor prognosis and therapy resistance in cisplatin-resistant gastric cancer [50], temozolamide chemoresistance in human gliomas [51], as well as paclitaxel-resistant breast cancer [52]. This evidence concerns the gene ATF4 and breast cancer.